keyword
MENU ▼
Read by QxMD icon Read
search

recurrent clostridium difficile

keyword
https://www.readbyqxmd.com/read/27930281/patients-with-risk-factors-for-complications-do-not-require-longer-antimicrobial-therapy-for-complicated-intra-abdominal-infection
#1
Rishi Rattan, Casey J Allen, Robert G Sawyer, John Mazuski, Therese M Duane, Reza Askari, Kaysie L Banton, Jeffrey A Claridge, Raul Coimbra, Joseph Cuschieri, E Patchen Dellinger, Heather L Evans, Christopher A Guidry, Preston R Miller, Patrick J ONeill, Ori D Rotstein, Michaela A West, Kimberley Popovsky, Nicholas Namias
A prospective, multicenter, randomized controlled trial found that four days of antibiotics for source-controlled complicated intra-abdominal infection resulted in similar outcomes when compared with a longer duration. We hypothesized that patients with specific risk factors for complications also had similar outcomes. Short-course patients with obesity, diabetes, or Acute Physiology and Chronic Health Evaluation II 15 from the STOP-IT trial were compared with longer duration patients. Outcomes included incidence of and days to infectious complications, mortality, and length of stay...
September 2016: American Surgeon
https://www.readbyqxmd.com/read/27923723/fecal-microbiota-transplantation-for-recurrent-clostridium-difficile-infection-in-patients-with-inflammatory-bowel-disease-a-single-center-experience
#2
Samantha M Chin, Jenny Sauk, Jasmine Mahabamunuge, Jess L Kaplan, Elizabeth L Hohmann, Hamed Khalili
No abstract text is available yet for this article.
December 3, 2016: Clinical Gastroenterology and Hepatology
https://www.readbyqxmd.com/read/27917075/management-of-clostridium-difficile-infection
#3
Layth S Al-Jashaami, Herbert L DuPont
Since the discovery of Clostridium difficile infection (CDI) in the 1970s, there has been an increase in the incidence, severity, and recurrence rate of the disease. We reviewed the recent CDI literature in PubMed published before February 28, 2016 that focused on advances in therapy. Despite a large number of studies describing methods for diagnosing the disease, there is currently no definitive test that identifies this infection with certainty, which complicates therapy. Recommended therapy for CDI includes oral metronidazole for mild cases and oral vancomycin or fidaxomicin for moderate to severe cases, each given for 10 to 14 days...
October 2016: Gastroenterology & Hepatology
https://www.readbyqxmd.com/read/27910000/a-review-of-experimental-and-off-label-therapies-for-clostridium-difficile-infection
#4
REVIEW
Csaba Fehér, Alex Soriano, Josep Mensa
In spite of increased awareness and the efforts taken to optimize Clostridium difficile infection (CDI) management, with the limited number of currently available antibiotics for C. difficile the halt of this increasing epidemic remains out of reach. There are, however, close to 80 alternative treatment methods with controversial anti-clostridial efficacy or in experimental phase today. Indeed, some of these therapies are expected to become acknowledged members of the recommended anti-CDI arsenal within the next few years...
December 1, 2016: Infectious Diseases and Therapy
https://www.readbyqxmd.com/read/27905086/bezlotoxumab-first-global-approval
#5
Anthony Markham
Bezlotoxumab (Zinplava™) is a human monoclonal antibody against Clostridium difficile toxin B developed by Merck & Co. In October 2016 it was approved in the USA for reducing the recurrence of C. difficile infection. This article summarizes the milestones in the development of bezlotoxumab leading to this first approval for use in patients receiving antibacterial drug treatment for C. difficile infection who are at high risk for recurrence of C. difficile infection.
November 30, 2016: Drugs
https://www.readbyqxmd.com/read/27891639/consensus-report-faecal-microbiota-transfer-clinical-applications-and-procedures
#6
REVIEW
J König, A Siebenhaar, C Högenauer, P Arkkila, M Nieuwdorp, T Norén, C Y Ponsioen, U Rosien, N G Rossen, R Satokari, A Stallmach, W de Vos, J Keller, R J Brummer
BACKGROUND: Faecal microbiota transplantation or transfer (FMT) aims at replacing or reinforcing the gut microbiota of a patient with the microbiota from a healthy donor. Not many controlled or randomised studies have been published evaluating the use of FMT for other diseases than Clostridium difficile infection, making it difficult for clinicians to decide on a suitable indication. AIM: To provide an expert consensus on current clinical indications, applications and methodological aspects of FMT...
January 2017: Alimentary Pharmacology & Therapeutics
https://www.readbyqxmd.com/read/27888332/interaction-of-gut-microbiota-with-bile-acid-metabolism-and-its-influence-on-disease-states
#7
REVIEW
Christopher Staley, Alexa R Weingarden, Alexander Khoruts, Michael J Sadowsky
Primary bile acids serve important roles in cholesterol metabolism, lipid digestion, host-microbe interactions, and regulatory pathways in the human host. While most bile acids are reabsorbed and recycled via enterohepatic cycling, ∼5% serve as substrates for bacterial biotransformation in the colon. Enzymes involved in various transformations have been characterized from cultured gut bacteria and reveal taxa-specific distribution. More recently, bioinformatic approaches have revealed greater diversity in isoforms of these enzymes, and the microbial species in which they are found...
November 25, 2016: Applied Microbiology and Biotechnology
https://www.readbyqxmd.com/read/27876339/diagnosis-and-treatment-of-clostridium-difficile-c-diff-colitis-review-of-the-literature-and-a-perspective-in-gynecologic-oncology
#8
REVIEW
Kristin N Taylor, Michael T McHale, Cheryl C Saenz, Steven C Plaxe
Clostridium difficile infection (CDI) is a major cause of nosocomial diarrhea with the potential for significant morbidity and mortality. Colonization in a susceptible individual, with risk factors such as prior antibiotic use, advanced age, or medical comorbidities, may result in symptomatic infection. Although patients with a gynecologic malignancy may be at a higher risk of developing CDI due to an increased likelihood of having one or more risk factors, data do not consistently support the idea that chemotherapy or cancer itself are independently associated with CDI...
November 19, 2016: Gynecologic Oncology
https://www.readbyqxmd.com/read/27866880/efficacy-of-sterile-fecal-filtrate-transfer-for-treating-patients-with-clostridium-difficile-infection
#9
Stephan J Ott, Georg H Waetzig, Ateequr Rehman, Jacqueline Moltzau-Anderson, Richa Bharti, Juris A Grasis, Liam Cassidy, Andreas Tholey, Helmut Fickenscher, Dirk Seegert, Philip Rosenstiel, Stefan Schreiber
BACKGROUND & AIMS: Fecal microbiota transplantation (FMT) is a highly effective therapy for recurrent Clostridium difficile infection (CDI). However, transferring undefined living bacteria entails uncontrollable risks for infectious and metabolic or malignant diseases, particularly in immunocompromised patients. We investigated whether sterile fecal filtrates (containing bacterial debris, proteins, antimicrobial compounds, metabolic products and oligonucleotides/DNA), rather than intact microorganisms, are effective in patients with CDI...
November 17, 2016: Gastroenterology
https://www.readbyqxmd.com/read/27864194/bezlotoxumab-approved-to-prevent-clostridium-difficile-recurrence
#10
Kate Traynor
No abstract text is available yet for this article.
December 1, 2016: American Journal of Health-system Pharmacy: AJHP
https://www.readbyqxmd.com/read/27862113/rethinking-strategies-to-select-antibiotic-therapy-in-cdi
#11
Teena Chopra, Ellie J C Goldstein, Sherwood L Gorbach
In recent years, Clostridium difficile infection (CDI) has become a global public health threat associated with increased morbidity, mortality, and economic burden, all of which are exacerbated with disease recurrence. Current guidelines informing treatment decisions are largely based on definitions of disease severity at diagnosis, with subjective components not well delineated across treatment algorithms and clinical trials. Furthermore, there is little evidence linking severity at onset to outcome. However, reducing the risk of recurrence may offer both a better outcome for the individual and decreased downstream economic impact...
November 9, 2016: Pharmacotherapy
https://www.readbyqxmd.com/read/27825317/epidemiology-and-outcome-of%C3%A2-clostridium-difficile%C3%A2-infections-in-patients-hospitalized-in-internal-medicine-%C3%A2-findings-from-the-nationwide-fadoi-practice-study
#12
Giorgio Cioni, Pierluigi Viale, Stefania Frasson, Francesco Cipollini, Francesco Menichetti, Nicola Petrosillo, Sergio Brunati, Patrizia Spigaglia, Chiara Vismara, Alessandra Bielli, Fabrizio Barbanti, Giancarlo Landini, Grazia Panigada, Gualberto Gussoni, Erminio Bonizzoni, Giovanni Pietro Gesu
BACKGROUND: Clostridium difficile (CD) is a leading cause of diarrhoea among hospitalized patients. The objective of this study was to evaluate the rate, the optimal diagnostic work-up, and outcome of CD infections (CDI) in Internal Medicine (IM) wards in Italy. METHODS: PRACTICE is an observational prospective study, involving 40 IM Units and evaluating all consecutive patients hospitalized during a 4-month period. CDI were defined in case of diarrhoea when both enzyme immunoassay for GDH, and test for A/B toxin were positive...
November 8, 2016: BMC Infectious Diseases
https://www.readbyqxmd.com/read/27822485/fecal-microbiota-transplantation-by-freeze-dried-oral-capsules-for-recurrent-clostridium-difficile-infection
#13
Michelle T Hecker, Mark E Obrenovich, Jennifer L Cadnum, Annette L Jencson, Alok K Jain, Edith Ho, Curtis J Donskey
No abstract text is available yet for this article.
April 2016: Open Forum Infectious Diseases
https://www.readbyqxmd.com/read/27817758/a-comprehensive-study-of-costs-associated-with-recurrent-clostridium-difficile-infection
#14
Rodrigo Rodrigues, Grant E Barber, Ashwin N Ananthakrishnan
BACKGROUND Clostridium difficile infection (CDI) is the most common healthcare-associated infection and is associated with considerable morbidity. Recurrent CDI is a key contributing factor to this morbidity. Despite an estimated 83,000 recurrences annually in the United States, there are few accurate estimates of costs associated with recurrent CDI. OBJECTIVE We performed this study (1) to identify the health consequences of recurrent CDI including need for repeat hospitalization, intensive care unit (ICU) stay, and surgery; (2) to determine costs associated with recurrent CDI and identify determinants of such costs; and (3) to compare the outcomes and costs of recurrent CDI to those who develop reinfection...
November 7, 2016: Infection Control and Hospital Epidemiology
https://www.readbyqxmd.com/read/27806252/identification-of-factors-impacting-recurrent-clostridium-difficile-infection-and-development-of-a-risk-evaluation-tool
#15
Bethanne P Carpenter, Erin K Hennessey, Alex M Bryant, Jad A Khoury, Andrew J Crannage
Recurrent Clostridium difficile infection (RCDI) is a growing concern, yet limited data exists to clarify which patients are at highest risk.  Identification of these patients may better inform decisions of those who may benefit from prophylactic intervention. The purpose of this study was to determine which factors are associated with the recurrence of Clostridium difficile infection (CDI) and to develop a risk stratification tool.  Methods. Patients readmitted within 10 weeks of positive C. difficile polymerase chain reaction (PCR) with symptoms were included in this retrospective case control study...
July 2016: Journal of Pharmacy & Pharmaceutical Sciences: a Publication of the Canadian Society for Pharmaceutical Sciences
https://www.readbyqxmd.com/read/27804875/clostridium-difficile-infection-associations-with-chemotherapy-radiation-therapy-and-targeting-therapy-treatments
#16
Avi Peretz, Izhar Ben Shlomo, Orna Nitzan, Luigi Bonavina, Pmela M Schaffer, Moshe Schaffer
BACKGROUND: Although mucositis, diarrhea, and constipation as well as immunosuppression are well recognized side-effects of cancer treatment, the underlying mechanisms including changes in the composition of gut microbiota and Clostridium difficile infection have not yet been thoroughly reviewed. OBJECTIVE: We herein set out to review the literature regarding the relations between cancer chemotherapy, radiation treatment, and Clostridium difficile-associated colitis...
October 28, 2016: Current Medicinal Chemistry
https://www.readbyqxmd.com/read/27796474/-clostridium-difficile-infection-what-is-currently-available-for-treatment
#17
A Stallmach
Clostridium difficile (C. difficile) is an anaerobic, Gram-positive, spore-forming, toxin-secreting bacillus. It is transmitted via a fecal-oral route and can be found in 1-3 % of the healthy population. Symptoms caused by C. difficile range from uncomplicated diarrhea to a toxic megacolon. The incidence, frequency of recurrence, and mortality rate of C. difficile infections (CDIs) have increased significantly over the past few decades. The most important risk factor is antibiotic treatment in elderly patients and patients with severe comorbidities...
December 2016: Der Internist
https://www.readbyqxmd.com/read/27785569/-clostridium-difficile-infections-in-geriatric-patients
#18
R Simmerlein, A Basta, M Gosch
Clostridium difficile is the main cause of nosocomial antibiotic-associated diarrhea in adults in Europe and North America. Infections with C. difficile typically occur in elderly patients with comorbidities and prior antibiotic therapy. Other risk factors are proton pump inhibitors, which are taken by many elderly patients. The main virulence factors are toxins A and B. The clinical spectrum ranges from asymptomatic colonization to severe disease with abdominal complications and sepsis. The current diagnostic gold standard is anaerobic culture but is impractical in routine use due to the long duration...
October 26, 2016: Zeitschrift Für Gerontologie und Geriatrie
https://www.readbyqxmd.com/read/27771207/determining-the-cause-of-recurrent-clostridium-difficile-infection-using-whole-genome-sequencing
#19
James Heng Chiak Sim, Cynthia Truong, Samuel S Minot, Nick Greenfield, Indre Budvytiene, Akshar Lohith, Victoria Anikst, Nader Pourmand, Niaz Banaei
Understanding the contribution of relapse and reinfection to recurrent Clostridium difficile infection (CDI) has implications for therapy and infection prevention, respectively. We used whole genome sequencing to determine the relation of C. difficile strains isolated from patients with recurrent CDI at an academic medical center in the United States. Thirty-five toxigenic C. difficile isolates from 16 patients with 19 recurrent CDI episodes with median time of 53.5days (range, 13-362) between episodes were whole genome sequenced on the Illumina MiSeq platform...
January 2017: Diagnostic Microbiology and Infectious Disease
https://www.readbyqxmd.com/read/27770261/epidemiology-and-recurrence-rates-of-clostridium-difficile-infections-in-germany-a-secondary-data-analysis
#20
Christoph Lübbert, Lisa Zimmermann, Julia Borchert, Bernd Hörner, Reinier Mutters, Arne C Rodloff
INTRODUCTION: Clostridium difficile infection (CDI) is the most common cause of health-care-associated infectious diarrhea. Recurrence rates are as high as 20-30% after standard treatment with metronidazole or vancomycin, and appear to be reduced for patients treated with fidaxomicin. According to the literature, the risk of CDI recurrence increases after the second relapse to 30-65%. Accurate data for Germany are not yet available. METHODS: Based on the research database of arvato health analytics (Munich, Germany), a secondary data analysis for the incidence, treatment characteristics and course of CDI was performed...
October 21, 2016: Infectious Diseases and Therapy
keyword
keyword
115341
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"